Immunome (NASDAQ:IMNM) Reaches New 12-Month High Following Analyst Upgrade

Immunome, Inc. (NASDAQ:IMNM) reached a new 52-week high during trading on Thursday after Truist Financial raised their price target on the stock from $37.00 to $38.00. Truist Financial currently has a buy rating on the stock. Immunome traded as high as $28.04 and last traded at $27.99, with a volume of 1561300 shares traded. The stock had previously closed at $26.25.

A number of other research analysts also recently issued reports on the company. Leerink Partners cut their price objective on Immunome from $37.00 to $33.00 and set an “outperform” rating for the company in a research note on Friday, May 15th. Barclays initiated coverage on shares of Immunome in a research note on Thursday, May 28th. They set an “overweight” rating and a $36.00 target price on the stock. Citigroup reaffirmed a “buy” rating on shares of Immunome in a report on Thursday, July 9th. Wedbush upped their price target on shares of Immunome from $31.00 to $35.00 and gave the stock an “outperform” rating in a research report on Wednesday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Immunome in a research note on Friday, July 17th. Twelve investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $34.64.

Insider Activity at Immunome

In related news, insider Robert Lechleider sold 55,000 shares of the business’s stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $22.62, for a total value of $1,244,100.00. Following the transaction, the insider directly owned 15,805 shares of the company’s stock, valued at approximately $357,509.10. The trade was a 77.68% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Isaac Barchas sold 11,048 shares of the business’s stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $27.25, for a total value of $301,058.00. Following the completion of the transaction, the director directly owned 92,211 shares in the company, valued at approximately $2,512,749.75. This represents a 10.70% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 682,310 shares of company stock valued at $15,675,566. 7.21% of the stock is owned by company insiders.

Trending Headlines about Immunome

Here are the key news stories impacting Immunome this week:

• Positive Sentiment: Truist raised its price target to $38 from $37 and maintained a Buy rating. The new target implies substantial potential upside and helped support investor interest in IMNM, which reached a fresh 52-week high following the upgrade. Truist price target update
• Positive Sentiment: An investment thesis highlighted two potential catalysts: FDA acceptance of varegacestat’s new drug application and a PDUFA decision date in April 2027. Investors are also watching IM-1021, Immunome’s Phase 1 ROR1 antibody-drug conjugate, with initial data expected in 2026. The company believes its proprietary TOP1 inhibitor payload could offer advantages in efficacy, resistance management and bystander effects. Immunome catalysts and pipeline analysis
• Positive Sentiment: Immunome’s second-quarter business update kept attention focused on its antibody-based oncology and infectious-disease pipeline, which remains the primary driver of the company’s valuation and future growth prospects. Immunome second-quarter 2026 results
• Neutral Sentiment: Director Isaac Barchas sold shares in several transactions from August 10 through August 12, including approximately 98,712 shares for about $2.6 million. The sales were conducted under a pre-arranged Rule 10b5-1 plan, reducing their usefulness as a signal of current management sentiment, although they may add short-term supply pressure. Immunome director sales SEC filing
• Negative Sentiment: Immunome reported a quarterly loss of $0.65 per share, wider than the expected loss of $0.51. The earnings miss underscores the company’s ongoing cash-burn and execution risks while its pipeline remains in development.

Hedge Funds Weigh In On Immunome

Institutional investors have recently bought and sold shares of the stock. Creative Planning lifted its stake in Immunome by 4.0% in the 3rd quarter. Creative Planning now owns 18,664 shares of the company’s stock worth $219,000 after purchasing an additional 710 shares in the last quarter. Russell Investments Group Ltd. grew its position in shares of Immunome by 14.4% during the fourth quarter. Russell Investments Group Ltd. now owns 7,417 shares of the company’s stock valued at $159,000 after purchasing an additional 935 shares in the last quarter. Allworth Financial LP purchased a new position in shares of Immunome during the second quarter valued at about $25,000. California State Teachers Retirement System increased its holdings in shares of Immunome by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 67,012 shares of the company’s stock worth $1,439,000 after purchasing an additional 1,167 shares during the last quarter. Finally, Assetmark Inc. increased its holdings in shares of Immunome by 46.6% in the first quarter. Assetmark Inc. now owns 4,535 shares of the company’s stock worth $99,000 after purchasing an additional 1,442 shares during the last quarter. 44.58% of the stock is owned by hedge funds and other institutional investors.

Immunome Price Performance

The company has a market capitalization of $3.00 billion, a PE ratio of -10.44 and a beta of 2.08. The business has a 50-day moving average of $22.02 and a 200 day moving average of $22.20.

Immunome (NASDAQ:IMNM) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.14). As a group, research analysts anticipate that Immunome, Inc. will post -2.06 EPS for the current year.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.